Review of studies · Supplements / medicine · 10 Sept 2026
Model finds weight regain after stopping semaglutide or tirzepatide
Source: Drug Topics
What the research found
Study (meta-analysis). Kow, Thiruchelvam and colleagues, writing in Endocrinology, Diabetes & Metabolism, used a Bayesian longitudinal model of reconstructed aggregate data after people stopped the GLP-1 medicines semaglutide or tirzepatide. Patients were estimated to regain about half of treatment-associated weight loss within roughly 7.5 months. Unadjusted regain looked slightly faster for tirzepatide than semaglutide; after adjustment there was no clear drug-specific difference. This is not a reason to start, stop, or replace a prescribed GLP-1 drug. Off-label longevity use is clinician-only. Not medical advice.
Evidence level: Review of studies. This is among the stronger kinds of evidence, but one study rarely settles a question.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34